| Name | Vamifeport |
| Description | Vamifeport (VIT-2763) is a novel orally active inhibitor that targets iron transport proteins and reduces markers of hemolysis in the SCD Townes model.VIT-2763 improves anemia and erythropoiesis, ameliorates vascular inflammation, and can be studied in β-thalassemia. |
| In vitro | Treatment with VIT-2763 (20μM) or hepcidin (1μM) for 20 minutes, 1 hour, 3 hours, 6 hours, and 18 hours induced dose-dependent internalization and ubiquitination of iron transporters in MDCK cells[1]. |
| In vivo | VIT-2763 (30, 100 mg/kg; orally twice daily for 36 days) restricted iron availability, ameliorating anemia and iron homeostasis dysregulation in the intermediate β-thalassemia Hbbth3/+ mouse model, improving erythropoiesis and correcting the proportion of myeloid precursors in the spleen of Hbbth3/+ mice[1]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 70 mg/mL (171.39 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (4.9 mM), Sonication is recommended.
|
| Keywords | VIT2763 | VIT 2763 | Ferroptosis |
| Inhibitors Related | Rosiglitazone | Hemin | Acetylcysteine | L-Glutamic acid | Sorafenib | Curcumin | L-Cystine | L-Glutamine | (-)-Epigallocatechin Gallate | Coenzyme Q10 | Baicalein | Sodium Molybdate |
| Related Compound Libraries | Ferroptosis Compound Library | Apoptosis Compound Library | Bioactive Compound Library | ReFRAME Related Library | Hematonosis Compound Library | Inhibitor Library | Immunology/Inflammation Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Fluorochemical Library |
United States
